anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Title

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 303,780
Current window 220,711-220,740
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all
18 30 60

Component

220,711-220,740 of 303,780

filter-aware
23
Includes a footnote regarding the exclusion of $8.4 million Orten acquisition cancellation in 3Q 2022.Hyzon | Investor Conference Presentation Deck | 24 slides · Hyzon
Conference presentation Investor relations Beat · Financials1 hit
24
Includes footnotes regarding legal contingencies and SEC settlements.Hyzon | Investor Conference Presentation Deck | 24 slides · Hyzon
Conference presentation Investor relations Beat · Financials1 hit
01
Slide 1
Hyzon | Results Presentation Deck | 19 slidesHyzon | Results Presentation Deck | 19 slides · Hyzon
Conference presentation Investor relations 1 hit
02
Hyzon | Results Presentation Deck | 19 slidesHyzon | Results Presentation Deck | 19 slides · Hyzon
Conference presentation Investor relations 1 hit
03
Includes both operational milestones and financial results/guidance.Hyzon | Results Presentation Deck | 19 slides · Hyzon
Conference presentation Investor relations Beat · Humble Origins1 hit
04
Hyzon | Results Presentation Deck | 19 slidesHyzon | Results Presentation Deck | 19 slides · Hyzon
Conference presentation Investor relations Beat · Humble Origins1 hit
06
The slide uses a process-like flow to connect technical features to quantitative performance outcomes.Hyzon | Results Presentation Deck | 19 slides · Hyzon
Conference presentation Investor relations Beat · Early Struggles1 hit
14
Hyzon | Results Presentation Deck | 19 slidesHyzon | Results Presentation Deck | 19 slides · Hyzon
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
15
The table includes both GAAP financial metrics and supplemental non-GAAP/operational data.Hyzon | Results Presentation Deck | 19 slides · Hyzon
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
16
The data shows a significant spike in legal/consulting/accounting fees in Q2 2023 due to SEC investigation accruals.Hyzon | Results Presentation Deck | 19 slides · Hyzon
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
17
The table includes footnotes explaining specific adjustments to the figures.Hyzon | Results Presentation Deck | 19 slides · Hyzon
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
18
Hyzon | Results Presentation Deck | 19 slidesHyzon | Results Presentation Deck | 19 slides · Hyzon
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
19
The table includes adjustments for fair value changes, stock-based compensation, and legal/regulatory matters.Hyzon | Results Presentation Deck | 19 slides · Hyzon
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
01
Slide 1
Immix Biopharma | Investor Presentation Deck | 46 slidesImmix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
02
Immix Biopharma | Investor Presentation Deck | 46 slidesImmix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
03
The slide highlights two distinct pipelines: TSTx (Tissue Specific Therapeutics) and NextGen CAR-T.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Problem (Identify pain)1 hit
04
The slide uses a wave-like visual to represent market segments and their associated financial opportunities.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
05
The table uses a standard pharmaceutical pipeline format, categorizing by clinical vs preclinical status and therapy type (CAR-T vs TSTx).Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
06
The slide uses a grouped bar chart to compare clinical outcomes across different patient segments (No BCMA, Yes BCMA, Overall).Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
07
Includes detailed source citations in the footer.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
08
Includes detailed source citations in the footer.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
09
The slide uses a two-column layout to separate milestones by drug candidate.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
10
The slide uses a side-by-side comparison of two proprietary technology platforms.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
11
Immix Biopharma | Investor Presentation Deck | 46 slidesImmix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
12
The slide uses a matrix structure to compare clinical outcomes against three key value propositions.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
15
Immix Biopharma | Investor Presentation Deck | 46 slidesImmix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
16
The slide compares two disease indications side-by-side with clinical metrics and competitive market context.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
17
The table uses a red dashed box to highlight the key clinical data rows (ORR, CR, ICANS, CRS).Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
18
The chart demonstrates deepening clinical responses over time, a key indicator of therapeutic efficacy in oncology trials.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
19
The slide uses a red dashed box to highlight the key efficacy metrics for comparison.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit